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Abstract 
Background: Epigenetic silencing mediated by CpG island methylation is a common feature of many cancers. Char-
acterizing aberrant DNA methylation changes associated with prostate carcinogenesis could potentially identify a 
tumour-specific methylation pattern, facilitating the early diagnosis of prostate cancer. The objective of the study was 
to assess the methylation status of 40 tumour suppressor genes in prostate cancer and healthy prostatic tissues.
Methods: We used methylation specific-multiplex ligation probe amplification (MS-MLPA) assay in two independent 
case series (training and validation set). The training set comprised samples of prostate cancer tissue (n = 40), healthy 
prostatic tissue adjacent to the tumor (n = 26), and healthy non prostatic tissue (n = 23), for a total of 89 DNA sam-
ples; the validation set was composed of 40 prostate cancer tissue samples and their adjacent healthy prostatic tissue, 
for a total of 80 DNA samples. Methylation specific-polymerase chain reaction (MSP) was used to confirm the results 
obtained in the validation set.
Results: We identified five highly methylated genes in prostate cancer: GSTP1, RARB, RASSF1, SCGB3A1, CCND2 
(P < 0.0001), with an area under the ROC curve varying between 0.89 (95 % CI 0.82–0.97) and 0.95 (95 % CI 0.90–1.00). 
Diagnostic accuracy ranged from 80 % (95 % CI 70–88) to 90 % (95 % CI 81–96). Moreover, a concordance rate ranging 
from 83 % (95 % CI 72–90) to 89 % (95 % CI 80–95) was observed between MS-MLPA and MSP.
Conclusions: Our preliminary results highlighted that hypermethylation of GSTP1, RARB, RASSF1, SCGB3A1 and CCND2 
was highly tumour-specific in prostate cancer tissue.
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Background
Prostate cancer (PCa) is the second most common malig-
nancy in men [1]. Current diagnostic methods have 
increased the number of patients diagnosed with early 
PCa, with a consequent benefit in survival, but have also 
led to overtreatment, reducing the cost-effectiveness of 
treatment [2, 3]. Low sensitivity and specificity of the 
prostate-specific antigen (PSA) test, along with false-
positive results and unnecessary biopsies for PSA values 
between 4 and 10 ng/ml, have created an urgent need for 
new biomarkers for PCa diagnosis [4, 5]. New biomark-
ers for PCa diagnosis have been studied with the purpose 
of improving sensitivity and specificity of PSA; some of 
these are FDA-approved, e.g. PCA3 testing in urine [6], 
but none has been implemented into clinical practice. For 
this reason, new, robust markers to accurately character-
ize PCa must be sought.
It is well known that epigenetic modifications such as 
DNA methylation in CpG islands are correlated with 
cancer development, indicating that such events could 
represent early phenomena of carcinogenesis [7]. For this 
reason, DNA methylation could be a potential biomarker 
for the early diagnosis of PCa. Tumour suppressor genes 
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are sometimes silenced by methylation and contribute to 
carcinogenesis, influencing mechanisms such as DNA 
repair and apoptosis [8]. Moreover, every tumour type 
has a specific methylation pattern which, when com-
pared with corresponding healthy tissue, could be use-
ful for diagnosis [9]. Several studies have focused on the 
relationship between modifications of epigenetic mecha-
nisms and prostate carcinogenesis [10].
In the present study we chose to analyze the meth-
ylation status of a panel of 40 tumour suppressor 
genes (TIMP3, APC, CDKN2A, MLH1, ATM, RARB, 
CDKND2B, HIC1, CHFR, BRCA1, CASP8, CDKN1B, 
PTEN, BRCA2, CD44, RASSF1, DAPK1, VHL, ESR1, 
TP73, FHIT, CADM1, CDH13, GSTP1, CCND2, 
SCGB3A1, BNIP3, DLC1, HLTF, SFRP5, H2AFX, CAC-
NA1AG, SFRP4, TWIST1, BCL2, CACNA1A, ID4, 
RUNX3, PRDM2 and TGIF) in PCa and healthy pros-
tatic tissue to identify a tumour-specific methylation 
pattern that could facilitate early diagnosis. We chose 
this 40 genes panel because some of the selected genes 
(GSTP1, TIMP3, RARB, CDKN2A, HIC, APC, CD44, 
RASSF1, CDH13, DAPK, BCL2, SFRP5, RUNX3) are 
already known to be frequently methylated in PCa [11, 
12]: GSTP1 is the most widely studied and it is methyl-
ated in 70–80 % of cases [9]. In addiction other genes, e.g. 
BRCA1, BRCA2, PTEN, TWIST1, are deregulated in vitro 
and in vivo due to their low expression or other genomic 
characteristics [13, 14]. The remaining genes have impor-
tant functions in different cancer-related processes, e.g. 
regulation of tumor growth, cell cycle control, differen-
tiation and proliferation, cell adhesion and DNA damage 
repair.
We used the relatively new methodology of methyla-
tion specific-multiplex ligation dependent probe amplifi-
cation (MS-MLPA) to evaluate epigenetic gene profiles in 
two independent cohorts of samples. This approach per-
mits methylation analysis of multiple targets in a single 
experiment [15] and has been successfully used to evalu-
ate the diagnostic or prognostic relevance of different 
markers in several tumor types including lung [16], rectal 
[17], breast [18] and bladder cancer [19, 20].
Methods
Case series
We analysed two independent case series: a training and 
validation set. For the training set, tissue samples were 
collected from patients submitted to prostatectomy 
between 2008 and 2011. Specifically, we collected 40 
samples of paraffin-embedded PCa tissue, 26 of healthy 
prostatic tissue adjacent to the tumour, and 23 of healthy 
non prostatic tissue (seminal vesicles and bladder neck). 
In the training set we chose random samples, a number 
of which were not paired between cancer and healthy 
prostatic tissue. All paired cancer/healthy samples for the 
validation set were collected from patients who under-
went prostatectomy in 2013. Specifically, we analysed 40 
prostate cancer tissue samples and their adjacent healthy 
prostatic tissue, for a total of 80 samples.
All patients gave written informed consent to take 
part in the study, which was reviewed and approved by 
the local Ethics Committee (“Comitato Etico Area Vasta 
Romagna e IRST”). All samples were retrieved from the 
Archives of the Pathology Unit of the Morgagni-Pieran-
toni Hospital in Forlì.
Macrodissection and DNA isolation
Cancer and healthy tissue was selected and macro-
dissected on the basis of hematoxylin-eosin sections. 
Healthy prostatic tissue was macrodissected at a distance 
of 7  mm from the tumour sample. DNA was extracted 
using QIAamp DNA FFPE Tissue (Qiagen, Milan, Italy), 
according to the manufacturer’s instructions, and quanti-
fied by spectrophotometry (NanoDrop ND-1000, Celbio, 
Milan, Italy). DNA from LNCaP cell line and peripheral 
blood of a healthy volunteer was extracted using QIAamp 
DNA Minikit (Qiagen), according to the manufacturer’s 
instructions.
MS‑MLPA
Methylation specific-multiplex ligation dependent probe 
amplification (MS-MLPA) was performed using at least 
50 ng of DNA dissolved in 1× TE buffer (Promega, Madi-
son, WI, USA). DNA isolated from LNCaP cell line was 
used as internal control for MS-MLPA analysis. The 
methylation status of 40 tumor suppressor gene pro-
moters was analysed using the ME001-C1 and ME003-
A1 kits (MRC-Holland, Amsterdam, The Netherlands) 
(Additional file 1: Table S1).
Two different probes that recognize two different sites 
of the promoter region were used for RASSF1, MLH1, 
SCGB3A1, CCND2, ID4, RARB, SFRP4, DLC1, H2AFX 
and HLTF genes. We considered the median value of the 
results of the two probes, assigning only one methylation 
value for each gene. CDKN2B gene was excluded from 
the analysis because its probe is sensitive to improper 
HhaI digestion in FFPE samples.
MS-MLPA analysis was performed following the manu-
facturer’s instructions. In brief, DNA was denatured and 
hybridization was performed by incubation at 60  °C for 
16–18 h. Ligation and digestion reactions were then per-
formed and samples were amplified by PCR. Digested 
probes could not be amplified exponentially during PCR 
and thus did not produce an amplification product. In 
contrast, if the DNA sample was methylated, DNA-probe 
hybrids were protected against HhaI enzyme digestion and 
the ligated probes generated an amplification product.
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Amplification products were analysed by ABI-3130 
genetic Analyzer (Applied Biosystem, Foster City, CA). 
Electropherograms obtained were evaluated using Gene 
Mapper software (Applied Biosystem) and the peak 
areas of each probe were exported to a homemade excel 
spreadsheet.
In accordance with the manufacturer’s instructions, we 
carried out “intrasample data normalization” by dividing 
the signal of each probe by the signal of each reference 
probe in the sample, thus creating as many ratios per 
probe as there were reference probes. We then calculated 
the median value of all probe ratios per probe, obtaining 
the normalization constant (NC). Finally, the methylation 
status of each probe was calculated by dividing the NC 
of a probe in the digested sample by the NC of the same 
probe in the undigested sample, and by multiplying this 
ratio by 100 to have a percentage value, as follows: 
We performed MS-MLPA analysis on four samples of 
peripheral blood of healthy volunteers, as controls for 
our analysis, finding absence of hypermethylation for all 
genes.
MS-MLPA reproducibility was assessed by perform-
ing three independent methylation profile analyses on 
LNCaP cell line. The methylation level for each gene was 
found to be the same in each experiment.
MSP
We used MSP as a confirmatory methodology to analyse 
the promoter methylation of five genes: GSTP1, RARB, 
RASSF1A, SCGB3A1 and CCND2. DNA was converted 
with sodium bisulphite using EZ DNA Methylation-
Gold™ kit (Zymo Research Corporation, Irvine, USA). 
The reactions were performed using 100  ng of DNA 
extracted from LNCaP (methylated control) and from the 
peripheral blood of a healthy volunteer (unmethylated 
control), and 150 ng of FFPE DNA.
We performed real-time PCR using SYBR-GREEN 
master mix (Biorad, Milan, Italy) and primers specific for 
bisulphite-converted. Primer sequences for Actin B were 
as follows: forward 5′-TGGTGATGGAGGAGGTTTAGT 
AAGT-3′, reverse 5′-AACCAATAAAACCTACTCCTCC 
CTTAA-3′, as described elsewhere [21]. Real-time PCR 
was performed using Rotor Gene 3000 (Diatech phar-
macogenetics, Jesi, Italy) under the following conditions: 
95 °C for 5 min, then 40 cycles of 94 °C for 30 s, 62 °C for 
60 s and 72 °C for 60 s. We then evaluated PCR product 
specificity with melt curve analysis and set the Ct thresh-
old at 0.02. For the subsequent preamplification PCR, 
10  µl of converted DNA was used when the Ct average 
value was ≥28, or 6 µl when <28.
NC digested sample
NC undigested sample
× 100
We performed a two-step MSP for RARB, RASSF1A, 
SCGB3A1 and CCND2 methylation analysis, as previ-
ously described by Zhu et  al. [22]. First, we performed 
a multiplex PCR using C1000™ Thermal Cycler (Biorad) 
containing 4 primer pairs (called ‘outer’) for each gene 
with AmpliTaq Gold PCR kit (Applied Biosystems) [22]. 
The outer primers targeted methylated and unmethylated 
sequences in the same loci to enhance the amount of the 
four specific fragments used as templates for the second 
real-time PCR. Primer sequences for RARB, RASSF1A, 
SCGB3A1 and CCND2 are described in Table  1. Real-
time PCR was carried out using SYBR-GREEN master 
mix (Biorad) and specific primers for methylated and 
unmethylated sequences (Table 1) for each gene. The pre-
vious preamplification products were diluted 1 to 10,000 
for RARB, RASSF1A and SCGB3A1 and 1–5000 for 
CCND2. The reaction was performed under the follow-
ing conditions: 95 °C for 5 min, then 40 cycles of 94 °C for 
30 s, 58 °C for 60 s, and 72 °C for 60 s.
For GSTP1 we only performed real-time PCR on 2 µl of 
bisulphite-converted DNA samples. Primers for methyl-
ated and unmethylated sequences are shown in Table 1. 
The reaction was performed under the following condi-
tions: 95 °C for 3 min, 40 cycles of 94 °C for 30 s, 56 °C for 
60 s and 72 °C for 60 s.
Statistical analysis
The sample size was calculated on the basis of the Bittner 
formula [23]: assuming α  =  0.01, β  =  0.10, a standard 
deviation of gene methylation intensity of measurements 
on the base-two logarithmic scale  =  0.7 and a 1.5-fold 
difference between the two classes (normal and tumour 
tissue). We compared clinical-pathological features in the 
training and validation sets using a non parametric statis-
tical test. A two-dimensional unsupervised hierarchical 
cluster analysis of the methylation profile was performed 
using Euclidean distance as similarity measure, and clus-
ters were combined using Ward’s method. Normality of 
data distribution was tested using the Shapiro–Wilk test. 
If data distribution was not normal (P > 0.05), a non-par-
ametric statistical test was used.
The relationship between methylation value and dif-
ferent subgroups of patients was analysed using the 
non-parametric statistical test (Wilcoxon test). For PCa 
samples, the relationship between methylation value and 
clinical-pathological features of patients were analysed 
using a non-parametric statistical test (Spearman corre-
lation for PSA levels considered as continuous variable 
and Wilcoxon for the other variables).
In validation set, the genes showing a significant P 
value in the Wilcoxon test were used to analyse the most 
discriminant cut-off values between PCa and P using 
ROC curve analysis. The true positive rates (sensitivity) 
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were plotted against the false positive rates (1-specificity) 
for all classification points. Cohen’s kappa coefficient was 
calculated to measure the concordance rate of MS-MLPA 
and MSP methods. A kappa value of more than 0.60 was 
regarded as showing strong agreement.
A stepwise logistic regression model was used in the 
validation set to analyse the relative risks (RR) and their 
95 % CIs for patient status (PCa/P) and methylation sta-
tus for selected genes.
All P values reported were two-sided and evaluated at 
the 0.05 level. Correction for multiple testing was per-
formed using the Benjamini–Hochberg approach. Clus-
ter analysis was performed with R software (version 
3.0.1). All other statistical analyses were performed with 
STATA/MP 10.1 for Windows (Stata Corp LP).
Results
The clinical-pathological characteristics are summarized 
in Table 2. We analysed two independent sets of samples: 
a training and a validation set. The sensitivity of the MS-
MLPA technique was evaluated by constructing a curve 
based on the generation of different proportions (5, 10, 
20, 40, 80, 100 %) of DNA derived from a prostate can-
cer cell line (LNCaP) with known methylation of GSTP1, 
RASSF1, SCGB3A1, CASP8, RARB, CD44, APC, RUNX3, 
CCND2, spiked in genomic DNA (control) from a blood 
sample of a healthy donor. We found good linearity and a 
positive correlation between methylated DNA input and 
MS-MLPA results (Fig. 1). We also showed that the MS-
MLPA technique is capable of detecting very low meth-
ylation percentages (at least 5 %).
Training set
The methylation status of 40 tumour suppressor genes 
was analysed in 89 samples. Unsupervised cluster analy-
sis for methylation profile identified two principal groups: 
one composed mainly of PCa tissue, the other mainly by 
healthy prostatic tissue adjacent to the tumour (defined 
as ‘P’) and healthy non prostatic tissue (‘C’) (Fig.  2). 
The median methylation levels for each gene in the 
three groups of samples are shown in Additional file  2: 
Table S2. Considering healthy and control samples, we 
observed statistically different methylation status for only 
2 genes: the median methylation status of CASP8 was 
9.92 (range 0.00–28.90) in P vs. 0.00 (range 0.00–9.50) 
in C (P  <  0.0001) and 9.45 (range 0.00–28.80) in P vs. 
0.00 (range 0.00–20.80) in C for SCGB3A1 (P = 0.0005) 
(Additional file 3: Figure S1). With the exception of these 
two genes, there were no differences in the methylation 
profile of the P and C samples. We compared the meth-
ylation status of the PCa and P groups to test the role of 
methylation in the early diagnosis of PCa. Comparative 
analysis showed that 12 genes had statistically higher 
methylation in tumour tissue (Table  3). No significant 
correlations were found between methylation status and 
clinical-pathological characteristics.
Table 1 Primer sequences
Gene Outer primer sequences Methylated primer sequences Unmethylated primer sequences
GSTP1 5′-TATCGTGGTTTATTTTTTAGTTCGA-3′
3′-ATAAAAAAATTCGAATCTCTCCGA-5′
5′-TATTGTGGTTTATTTTTTAGTTTGA-3′
3′-ATAAAAAAATTCAAATCTCTCCAAA-5′
RARB 5′-TATGCGAGTTGTTTGAGGATTGGGA-3′
3′-AATAATCATTTACCATTTTCCAAACTTA-5′
5′-TGTGAGAACGCGAGCGATTC-3′
3′-CGACCAATCCAACCGAAACGA-5′
5′-TTGGGATGTTGAGAATGTGAGTGATTT-3′
3′-CTTACTCAACCAATCCAACCAAAACAA-5′
RASSF1 5′-GTTTAGTTTGGATTTTGGGGGAG-3′
3′-CCCACAACTCAATAAACTCAATAAACTCAAACTC-5′
5′-GGGTTCGTTTTGTGGTTTCGTTC-3′
3′-TAACCCGATTAAACCCGTACTTCG-5′
5′-GGGGTTTGTTTTGTGGTTTTGTTT-3′
3′-AACATAACCCAATTAAACCCATACTTCA-5′
SCGB3A1 5′-AGTGAGGATATTTAGAGAAATTTAGG-3′
3′-ATCCCTACCTCTAATCCCAA-5′
5′-GCGTCGAGGTTAGTTCG-3′
3′-GTAAACGCCTTCTACGCCTAA-5′
5′-GTGTTGAGGTTAGTTTTGAAGA-3′
3′-TAAACACCTTCTACACCTAAAA-5′
CCND2 5′-TATTTTTTGTAAAGATAGTTTTGATTTAAGG-3′
3′-TTTCCCCGAAAACATAAAACCTCC-5′
5′-GGCGGATTTTATCGTAGTCG-3′
3′-CTCCACGCTCGATCCTTCG-5′
5′-AGAGTATGTGTTAGGGTTGATT-3′
3′-ACATCCTCACCAACCTCCA-5′
Table 2 Case series
a The two groups were equally distributed for age, Gleason score, pathological 
stage and PSA. The Chi square test was used for age and Gleason score to 
determine statistical differences between training and validation sets; the Fisher 
test was used for pathological stage and the Wilcoxon test for PSA value
Training set
n = 40
Validation set
n = 40
P valuea
Age, years
 ≤70 32 33 0.775
 >70 8 7
Gleason score
 ≤6 18 13 0.251
 >6 22 27
Pathological stage
 T2a 5 5
 T2b 1 0
 T2c 17 16 0.554
 T3a 12 17
 T3b 5 2
Median PSA (range) 6.77 (3.19–33.14) 5.81 (2.65–24.00) 0.1988
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Validation set
Forty PCa tissue samples and 40 P samples were evalu-
ated for the same panel of tumour suppressor genes. As 
in the training set, we identified two cluster groups in 
validation set, one composed of PCa samples, the other 
of P samples, the latter showing a lower methylation pro-
file (Fig. 3). The median methylation levels for each gene 
in the two groups of samples are shown in Additional 
file 2: Table S2. Comparative analysis confirmed that gene 
methylation status differed between tumour and healthy 
tissue in 9 out of 12 genes (Table 3). We then performed 
receiver operating characteristic (ROC) curve analyses 
for each of these genes (Fig. 4): five genes (GSTP1, RARB, 
RASSF1, SCGB3A1 and CCND2) were highly specific in 
discriminating between prostate cancer and adjacent 
normal tissue, with an area under ROC curve (AUC) 
ranging from 0.89 (95 % CI 0.82–0.97) to 0.95 (95 % CI 
0.90–1.00). ROC curve analysis also identified the best 
methylation cut-off: we considered the promoters show-
ing a ratio ≥0.20 as methylated, while those with a ratio 
<0.20 were considered as unmethylated. The overall 
diagnostic accuracy for the five genes varied between 80 
and 90 % (Table 4). A stepwise regression analysis with a 
0.20 probability removal was carried out in the validation 
set to evaluate the capability of GSTP1, RARB, RASSF1, 
SCGB3A1 and CCND2 gene methylation to predict the 
risk of PCa. RARB and SCGB3A1 proved to be independ-
ent variables that indicated a relative risk of there being 
prostate cancer of 1.14 (95  % CI 0.99–1.31, P  =  0.058) 
and 1.10 (95 % CI 1.01–1.21, P = 0.028), respectively.
Correlation analysis of methylation status and clin-
ical-pathological characteristics showed that RUNX3 
was significantly correlated with PSA levels: its meth-
ylation status was positively associated with PSA lev-
els (P  =  0.0001). We also performed methylation 
specific PCR (MSP) analysis for GSTP1, RARB, RASSF1, 
SCGB3A1 and CCND2 to confirm their methylation sta-
tus previously identified with the MS-MLPA analysis. We 
used Cohen’s kappa coefficient to assess the concordance 
rate between MS-MLPA and MSP analyses. The kappa 
coefficient was greater than 0.6 for each gene, indicating 
strong agreement that ranged from 83 to 89 %.
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CCND2 R² =0.992
RUNX3 R² =0.923
SCGB3A1 R² =0.999
RARB R² =0.996
APC  R² =0.993
CASP8  R² =0.997
CD44 R² =0.997
RASSF1  R² =0.999
GSTP1   R² =0.999
Fig. 1 Correlation between different percentages of methylated DNA input (LNCaP cell line, X axis) and methylation percentage results obtained 
using the MS-MLPA technique (Y axis). Results for CCND2, RUNX3, SCGB3A1, RARB, APC, CASP8, CD44, RASSF1 and GSTP1 are reported with correspond-
ing R2 results
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We also evaluated the global methylation status of 28 
paired cancer and normal samples using ELISA assay 
(MethyFlash Methylated DNA Quantification Kit, Epi-
gentek, NY, USA) and obtained a global methylation 
percentage. Nineteen (68  %) patients showed a 5-mC 
(5-methylcytosine) % decrease in cancer tissue compared 
to normal adjacent tissue (data not shown).
We compared early tumors of PCa (defined as Gleason 
score ≤6 or T2 pathological stage) with normal prostate 
tissue (P), but we also compared all PCa with P. We iden-
tified the same statistically significant differences in the 
two comparisons except for these genes: CDH13, RUNX3 
in training set and HIC1 in validation set. For training set, 
CDH13 and RUNX3 had statistical significance in all PCa 
Fig. 2 Hierarchical cluster analysis of methylation status of 40 tumour suppressor genes (training set): the blue colour indicates an absence of 
methylation in the genes, whereas red indicates high methylation; shades of colour indicate intermediate methylation status. The 40 genes are shown 
along the bottom, while the samples are represented in the column on the right
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vs. P comparison but not in early tumors. For the valida-
tion set, HIC1 acquired statistical significance in early 
tumors but this was not confirmed in all PCa series vs. P.
Discussion
Aberrant DNA methylation usually occurs at an early 
stage in cancer, rendering DNA methylation biomarkers 
good candidates for early cancer detection. In the present 
study we used an MS-MLPA approach to identify a panel 
of tumour suppressor genes differentially methylated in 
prostate cancer with respect to healthy tissue. The MS-
MLPA method is a highly sensitive method [17, 20, 24] 
that is capable of identifying several promoter regions 
using a small quantity of DNA [25, 26]. We detected 12 
genes with high methylation levels in tumour tissue com-
pared to healthy tissue in the training set, nine of which 
were subsequently confirmed in the validation set. Of 
these nine genes, five (GSTP1, RARB, RASSF1, SCGB3A1 
and CCND2) discriminated between tumour and healthy 
tissue with a diagnostic accuracy of ≥80 %. As the MS-
MLPA technique is designed to assess the methylation 
status of single CpG dinucleotides, a negative finding 
at a single CpG dinucleotide is not sufficient to rule out 
methylation at a given island. For this reason we con-
firmed the methylation status of these five genes by MSP, 
a simpler and less expensive method, based on bisulphite 
DNA conversion.
The concordance rate between MS-MLPA (based on 
HhaI enzymatic cleavage of unmethylated sequences) and 
MSP (based on bisulphite conversion of unmethylated 
cytosines to uracils) revealed strong agreement between 
the two methods.
Although hypermethylation in the promoter regions 
of tumour suppressor genes is often observed in cancer, 
global DNA hypomethylation occurs in cancer tissue 
with respect to normal tissue [27, 28]. In line with these 
literature data, we observed a lower 5-mC % in cancer 
compared to normal adjacent tissue in our small cohort 
of 28 patients (validation set) (data not shown).
Numerous studies investigating GSTP1, RARB and 
RASSF1 DNA promoter methylation have reported that 
hypermethylation in prostate tumour tissue may repre-
sent a biomarker of early cancer diagnosis, in accordance 
with our results [29, 30]. There are few studies in litera-
ture on the hypermethylation of SCGB3A1 and CCND2 
in prostate tumour tissue. SCGB3A1 is a growth-inhibi-
tory cytokine which is downregulated in the majority of 
prostate, breast, lung, pancreatic and nasopharyngeal 
cancers due to DNA promoter hypermethylation [31]. 
CCND2 is a cell cycle-regulatory gene whose altered 
expression makes it function as an oncogene or tumor 
suppressor gene [32]. Padar et al. [33] observed an asso-
ciation between CCND2 inactivation and promoter 
region hypermethylation, reporting a positive correla-
tion between methylation frequency and high Gleason 
score group suggestive of a prognostic role of the gene. 
Although SCGB3A1 and CCND2 methylation in prostate 
cancer has been reported, the possibility of using these 
markers for the early diagnosis of PCa has never been 
fully investigated.
Table 3 Difference in methylated genes between cancer (PCa) samples and healthy (P) samples adjacent to the tumour
AUC area under ROC curve
* Wilcoxon test: prostate cancer samples (PCa) vs. healthy adjacent prostate samples (P)
Gene Training set Validation set AUC Validation set 
(95 % CI)
Median value (range) P value* Median value (range) P value*
PCa P PCa P
GSTP1 69.70 (0.00–100.00) 0.00 (0.00–18.20) <0.0001 35.50 (0.00–100.00) 2.81 (0.00–30.18) <0.0001 0.89 (0.82–0.97)
RASSF1 49.25 (11.10–100.00) 5.00 (0.00–45.60) <0.0001 46.69 (9.88–79.98) 9.63 (0.00–74.81) <0.0001 0.92 (0.85–0.98)
CCND2 35.10 (4.40–94.60) 5.75 (0.00–27.10) <0.0001 33.29 (7.26–100.00) 5.41 (0.00–38.45) <0.0001 0.92 (0.86–0.98)
SCGB3A1 65.90 (12.40–100.00) 9.45 (0.00–28.80) <0.0001 56.47 (0.00–100.00) 10.35 (0.00–35.04) <0.0001 0.95 (0.90–1.00)
RARB 29.95 (4.60–71.50) 4.65 (0.00–16.10) <0.0001 35.89 (2.29–100.00) 4.55 (0.00–18.71) <0.0001 0.94 (0.88–0.99)
ID4 22.65 (4.30–100.00) 5.15 (0.00–11.90) <0.0001 14.41 (0.00–45.32) 5.08 (0.00–16.08) <0.0001 0.86 (0.78–0.94)
CACNA1A 12.95 (0.00–100.00) 0.00 (0.00–2.13) 0.0001 6.32 (0.00–68.89) 0.00 (0.00–14.94) 0.0001 0.74 (0.64–0.84)
SFRP5 7.50 (0.00–29.30) 0.00 (0.00–0.00) <0.0001 8.35 (0.00–39.01) 0.00 (0.00–10.79) <0.0001 0.82 (0.73–0.91)
APC 32.55 (0.00–71.00) 4.88 (0.00–59.10) 0.0001 36.77 (0.00–91.80) 5.89 (0.00–38.90) <0.0001 0.84 (0.75–0.93)
CD44 5.60 (0.00–57.40) 0.00 (0.00–10.30) 0.0009 5.92 (0.00–59.33) 4.08 (0.00–29.70) 0.1391 –
CDH13 0.00 (0.00–39.00) 0.00 (0.00–14.40) 0.0087 9.43 (0.00–41.21) 5.99 (0.00–27.62) 0.0557 –
RUNX3 3.75 (0.00–44.10) 0.00 (0.00–29.60) 0.0088 9.71 (0.00–47.22) 8.38 (0.00–44.90) 0.3351 –
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We also highlighted a similar methylation profile for 
healthy prostatic tissue adjacent to the tumour and 
healthy non prostatic tissue, with the exception of CASP8 
and SCGB3A1, which showed a statistically higher meth-
ylation in the former.
The methylation level of SCGB3A1 gradually increased 
from low in healthy non prostatic tissue, to intermediate 
in healthy prostatic samples, and to high in PCa tissue, 
suggesting a role in early tumourigenesis. For this reason, 
we hypothesised that SCGB3A1 could be an important 
biomarker for cancer in non cancerous prostatic tissue. 
Noteworthy, RASSF1 and SCGB3A1 had similar sensitiv-
ity values both in early and in locally advanced tumors 
(Table  4), thus demonstrating they could be potentially 
Fig. 3 Hierarchical cluster analysis of methylation status of 40 tumour suppressor genes (validation set): the blue colour indicates an absence of 
methylation in the genes, whereas red indicates high methylation; shades of colour indicate intermediate methylation status. The 40 genes are shown 
along the bottom, while the samples are represented in the column on the right
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involved in the very earliest phases of carcinogenesis. 
This is an important characteristic for early diagnostic 
biomarkers.
In recent years, DNA promoter methylation has also 
been acknowledged as a biomarker to support clini-
cal decision-making for suspected PCa. An important 
clinical problem is to determine which patients with 
a suspicion of PCa and initial negative biopsy should 
be referred for a second biopsy [34]. As some studies 
have recently suggested that false-negative first biop-
sies occur in around 20–25 % of patients [35–37], it is 
essential to unmask the cases of PCa among the nega-
tive core biopsies, thus eliminating the need for a repeat 
biopsy. Two studies, the MATLOC study [35] and the 
more recent DOCUMENT study [36] have shown that 
three methylation markers (GSTP1, APC and RASSF1) 
are capable of identifying PCa among negative core 
biopsies.
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Fig. 4 ROC curve analysis of the five genes highly specific in discriminating prostate cancer from healthy tissue: a GSTP1, b RARB, c RASSF1,  
d SCGB3A1, and e CCND2
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The role of GSTP1, RARB and RASSF1 DNA promoter 
methylation as a non invasive biomarker for the early diag-
nosis of PCa has been widely investigated in body fluids 
[38, 39] using the MSP technique. A number of authors 
have also suggested that urine cell-free DNA could repre-
sent a source of cost-effective and non invasive biomark-
ers [36, 40–42], e.g. specific promoter region methylation. 
To the best of our knowledge, SCGB3A1 and CCND2 have 
not been hypothesised as potential non invasive biomark-
ers for early diagnosis and it would thus be interesting to 
analyse them in urine or plasma cell-free DNA.
Conclusions
Our preliminary results, obtained in a single-institution 
study with limited enrolment, showed that the hyper-
methylation of GSTP1, RARB, RASSF1, SCGB3A1 and 
CCND2 was highly tumour-specific in prostate cancer 
tissue. We verified the potential of these markers in two 
independent case series and using two different tech-
niques. Larger prospective studies are now needed to 
investigate these genes in body fluids.
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Table 4 Diagnostic accuracy
a Early tumors: GS ≤ 6 or T2
b Locally advanced tumors: GS > 6 or T3
Gene Overall sensitivity 
(n = 40) %
Early tumors sensitivity 
(n = 22) %a
Locally advanced  
tumors sensitivity  
(n = 18) %b
Overall  
specificity  
(n = 40) %
Overall 
accuracy 
(n = 80) %
RARB
Rate (95 % CI) 30/40
75 (59–87)
15/22
68 (49–87)
15/18
83 (66–100)
40/40
100 (91–100)
70/80
88 (78–94)
GSTP1
Rate (95 % CI) 28/40
70 (53–83)
14/22
64 (44–84)
14/18
78 (59–97)
37/40
93 (80–98)
65/80
81 (71–89)
CCND2
Rate (95 % CI) 27/40
68 (51–81)
12/22
55 (34–76)
15/18
83 (66–100)
37/40
93 (80–98)
64/80
80 (70–88)
RASSF1
Rate (95 % CI) 35/40
88 (73–96)
18/22
82 (66–98)
17/18
94 (83–100)
33/40
83 (67–93)
68/80
85 (75–92)
SCGB3A1
Rate (95 % CI) 38/40
95 (83–99)
21/22
95 (86–100)
17/18
94 (83–100)
34/40
85 (70–94)
72/80
90 (81–96)
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